Literature DB >> 25908321

Examining the factor structure of the Clinical Opiate Withdrawal Scale: A secondary data analysis from the National Drug Abuse Treatment Clinical Trials Network (CTN) 0003.

Celestina Barbosa-Leiker1, Sterling McPherson2, Mary Rose Mamey3, G Leonard Burns3, Matthew E Layton4, John Roll5, Walter Ling6.   

Abstract

BACKGROUND: The Clinical Opiate Withdrawal Scale (COWS) is used to assess withdrawal in clinical trials and practice. The aims of this study were to examine the inter-item correlations and factor structure of the COWS in opioid-dependent men and women.
METHODS: This is a secondary data analysis of the National Drug Abuse Treatment Clinical Trials Network 0003, a randomized clinical trial that compared buprenorphine/naloxone tapering strategies. The trial included 11 sites in 10 US cities. Participants were opioid-dependent individuals (n=516) that had data on the COWS. The COWS at study baseline was analyzed in this study.
RESULTS: Inter-item correlations showed weak to moderate relationships among the items. A 1-factor model did not fit the data for men (comparative fit index (CFI)=.801, root mean square error of approximation (RMSEA)=.073, weighted root mean square residual (WRMR)=1.132) or women (CFI=.694, RMSEA=.071, WRMR=.933), where resting pulse rate was not related to withdrawal for men, and yawning and gooseflesh skin was not related to withdrawal for women. A reduced model comprised of only the 8 items that were significantly related to the construct of withdrawal in both men and women, and an exploratory 2-factor model, were also assessed but not retained due to inconsistencies across gender.
CONCLUSIONS: When traditional psychometric models are applied to the COWS, it appears that the scale may not relate to a single underlying construct of withdrawal. Further research testing the hypothesized factor structure in other opioid-dependent samples is needed.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Clinical Opiate Withdrawal Scale; Opiate dependence; Opiate withdrawal; Psychometrics

Mesh:

Substances:

Year:  2015        PMID: 25908321      PMCID: PMC4458161          DOI: 10.1016/j.drugalcdep.2015.03.036

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  14 in total

1.  Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet.

Authors:  L Amass; J B Kamien; S K Mikulich
Journal:  Drug Alcohol Depend       Date:  2000-02-01       Impact factor: 4.492

2.  Pleiotropic opioid regulation of spinal endomorphin 2 release and its adaptations to opioid withdrawal are sexually dimorphic.

Authors:  Sumita Chakrabarti; Nai-Jiang Liu; James E Zadina; Tarak Sharma; Alan R Gintzler
Journal:  J Pharmacol Exp Ther       Date:  2011-10-04       Impact factor: 4.030

3.  Sex and opioid maintenance dose influence response to naloxone in opioid-dependent humans: a retrospective analysis.

Authors:  Mohit P Chopra; Zachary Feldman; Michael J Mancino; Alison Oliveto
Journal:  Pharmacol Biochem Behav       Date:  2008-10       Impact factor: 3.533

4.  Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence.

Authors:  Douglas M Ziedonis; Leslie Amass; Marc Steinberg; George Woody; Jonathan Krejci; Jeffrey J Annon; Allan J Cohen; Nancy Waite-O'Brien; Susan M Stine; Dennis McCarty; Malcolm S Reid; Lawrence S Brown; Robert Maslansky; Theresa Winhusen; Dean Babcock; Greg Brigham; Joan Muir; Deborah Orr; Betty J Buchan; Terry Horton; Walter Ling
Journal:  Drug Alcohol Depend       Date:  2008-09-20       Impact factor: 4.492

Review 5.  Longitudinal missing data strategies for substance use clinical trials using generalized estimating equations: an example with a buprenorphine trial.

Authors:  Sterling McPherson; Celestina Barbosa-Leiker; Michael McDonell; Donelle Howell; John Roll
Journal:  Hum Psychopharmacol       Date:  2013-09       Impact factor: 1.672

6.  Psychometric properties of the adjective rating scale for withdrawal across treatment groups, gender, and over time.

Authors:  Celestina Barbosa-Leiker; Sterling McPherson; Mary Rose Mamey; G Leonard Burns; John Roll
Journal:  J Subst Abuse Treat       Date:  2013-09-24

Review 7.  Importance of sex to pain and its amelioration; relevance of spinal estrogens and its membrane receptors.

Authors:  Alan R Gintzler; Nai-Jiang Liu
Journal:  Front Neuroendocrinol       Date:  2012-10-02       Impact factor: 8.606

8.  Buprenorphine tapering schedule and illicit opioid use.

Authors:  Walter Ling; Maureen Hillhouse; Catherine Domier; Geetha Doraimani; Jeremy Hunter; Christie Thomas; Jessica Jenkins; Albert Hasson; Jeffrey Annon; Andrew Saxon; Jeffrey Selzer; Joshua Boverman; Richard Bilangi
Journal:  Addiction       Date:  2009-02       Impact factor: 6.526

9.  A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts.

Authors:  W K Bickel; M L Stitzer; G E Bigelow; I A Liebson; D R Jasinski; R E Johnson
Journal:  Clin Pharmacol Ther       Date:  1988-01       Impact factor: 6.875

Review 10.  The Clinical Opiate Withdrawal Scale (COWS).

Authors:  Donald R Wesson; Walter Ling
Journal:  J Psychoactive Drugs       Date:  2003 Apr-Jun
View more
  1 in total

1.  Preliminary evidence of different and clinically meaningful opioid withdrawal phenotypes.

Authors:  Kelly E Dunn; Elise M Weerts; Andrew S Huhn; Jennifer R Schroeder; David Andrew Tompkins; George E Bigelow; Eric C Strain
Journal:  Addict Biol       Date:  2018-10-08       Impact factor: 4.280

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.